OncoMatch/Brain Cancer — Glioblastoma (GBM)/EGFR
Brain Cancer — Glioblastoma (GBM)EGFR Clinical Trials
EGFR amplification occurs in ~40% of IDH-wild-type GBM, and the EGFRvIII variant (exon 2–7 deletion) is present in ~25%. EGFR-directed therapy in GBM remains an unmet need — small-molecule inhibitors have limited CNS penetration, and the EGFR-directed ADC depatuxizumab mafodotin failed to improve OS in a Phase 3 trial. Trials investigate new-generation EGFR inhibitors, EGFRvIII-targeting CAR-T cells, and bispecific antibody constructs with improved brain penetration.
Top recruiting EGFR Brain Cancer — Glioblastoma (GBM) trials
Ranked by phase and US site count.
See all trials matched to your profile →Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Emory University
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study
Li-kun Chen
Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma
Tianjin Medical University General Hospital
More EGFR Brain Cancer — Glioblastoma (GBM) trials
2 international trials (no US sites)
Browse other molecular targets with active Brain Cancer — Glioblastoma (GBM) trials.